Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results, Beats Expectations By $0.27 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) announced its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.27, FiscalAI reports. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The company had revenue of $162.05 million during the quarter, compared to analyst estimates of $150.30 million.

Tarsus Pharmaceuticals Stock Down 0.4%

NASDAQ TARS traded down $0.25 during trading on Wednesday, reaching $64.79. 931,710 shares of the company’s stock traded hands, compared to its average volume of 564,715. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market cap of $2.79 billion, a price-to-earnings ratio of -39.99 and a beta of 0.52. The company’s 50 day simple moving average is $69.03 and its two-hundred day simple moving average is $72.00. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $85.25.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 4,174 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $279,658.00. Following the transaction, the insider owned 35,028 shares of the company’s stock, valued at $2,346,876. The trade was a 10.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bobak R. Azamian sold 11,964 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $801,588.00. Following the completion of the transaction, the chief executive officer directly owned 33,421 shares in the company, valued at approximately $2,239,207. The trade was a 26.36% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 79,391 shares of company stock worth $5,432,035. Company insiders own 8.97% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TARS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Tarsus Pharmaceuticals by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after buying an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Tarsus Pharmaceuticals by 2.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after buying an additional 1,394 shares during the last quarter. Jane Street Group LLC grew its position in shares of Tarsus Pharmaceuticals by 105.8% in the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock worth $537,000 after buying an additional 190,000 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Tarsus Pharmaceuticals by 402.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 140,610 shares of the company’s stock worth $5,696,000 after buying an additional 112,637 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Tarsus Pharmaceuticals by 12.3% in the 2nd quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock worth $37,614,000 after buying an additional 101,978 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of research analyst reports. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $90.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.